In general, drug treatment of hypertension is started with a diuretic. If such therapy is not successful another hypotensive drug is added, either a specific sympatholytic agent or methyldopa.
Brit. med. 7., 1967, 2, 598-600 In general, drug treatment of hypertension is started with a diuretic. If such therapy is not successful another hypotensive drug is added, either a specific sympatholytic agent or methyldopa.
In order to be as objective as possible regarding which of these methods of treatment is the best a double-blind trial was carried out; this included two of the known hypotensive drugs, guanethidine (Ismelin) and methyldopa (Aldomet), and two new drugs, guanoxan (Envacar) and guanoclor (Vatensol) .
Chemistry and Pharmacology
Guanethidine is a sympatholytic agent (Maxwell et al., 1959) , and its effect is predominantly a lowering of the blood pressure in the erect position, whereas only a slight reduction is obtained In the supine position (Page and Dustan, 1959) . Guanethidine reduces the concentration of catecholamine both centrally and peripherally, but not in the superior parts of the central nervous system. Intestinal absorption is constant, its elimination is mainly renal and slow, and therefore the dose should be determined cautiously in cases of impairment of renal function. When the drug is administered intravenously the cardiac output and renal blood flow are distinctly reduced, and bradycardia is a characteristic finding.
Methyldopa (alpha-methyl-3-4-dihydroxyphenyl-alanine) is a decarboxylase inhibitor. Absorption takes place rapidly, but varies from patient to patient-a fact without positive correlation to the antihypertensive effect. The mechanism of the drug has not yet been explained in detail. Its decarboxylase inhibitory action is not alone responsible for the antihypertensive result; other decarboxylase inhibitors have no effect at all on the raised blood pressure. Metabolites of methyldopa such as methylnoradrenaline could be the effective agents; a replacement of noradrenaline with this metabolite in tissue stores might act as a false transmitter on stimulation. Methylnoradrenaline has in itself some, though poor, pressor effect. This hypothesis could explain the poor orthostatic effect of methyldopa and the missing clinical sympatholytic action (Sannerstedt et al., 1962 Onesti et al., 1964 Prescott et al., 1966) .
Guanoxan is 2-guanidinomethylbenzo-1, 4-dioxan. Consequently it is a guanethidine-ring with benzodioxane in the side chain. Guanoxan causes a reduction in the concentration of catecholamines in both the hypothalamus and the adrenal medulla, and peripherally. It has been shown that cats treated with guanoxan present reduced avoiding reactions and inhibited vasoconstrictive response in the skin on hypothalamic stimulation. In dogs treated with guanoxan a reduced effect of injected adrenaline due to adrenergic blockade has been found (Brit med. 7., 1964a; Davey and Reinert, 1965) ; similar findings were made with benzodioxane alone.
In animal experiments guanoxan differs from guanethidine in that it blocks the alpha-receptors and reduces the concentration of catecholamine in the hypothalamus. On Since guanethidine and methyldopa were introduced for the treatment of hypertension in the late 'fifties many reports have been published on their clinical application and side-effects (Cass et al., 1960; Dollery et al., 1960; Oates et al., 1960; Sannerstedt et al., 1961 ; Bayliss and Harvey-Smith, 1962; Daley and Evans, 1962; Gillespie et al., 1962; Lauwers et al., 1963; Lowther and Turner, 1963) .
Only a few clinical trials of guanoxan and guanoclor have been published. With respect to the former drug, two independent studies showed a good degree of control in 58% of 62 patients (Peart and MacMahon, 1964) and 48 patients (Montuschi and Lovel, 1964) . The side-effects reported were lack of energy, nausea, diarrhoea, and impotence, as well as failure of ejaculation. On guanoclor the blood pressure was well controlled in 60% of 39 patients (Lawrie et al., 1964 The dosage was increased until satisfactory response was obtained-that is, no reduction in the blood pressure in spite of higher doses-or the occurrence of prohibitive side-effects. In cases where the response was satisfactory the requisite dose was maintained for 2-3 controls-that is, one to two months.
At the beginning of the trial and when any change of drug was made, the transition took place gradually, the drug in use being tailed off durng the increase in dosage of the next.
The sequence of the drugs was fixed systematically, so that no sequence became more frequent than others. Each drug was given for periods of two to six months, on an average for three and a half months.
Results
One of the four drugs had a satisfactory effect in only 3 of the 11 patients who started with it. In the remaining eight it considerably. In seven patients treated with guanoxan and in 14 treated with guanethidine the side-effects were so troublesome that the dose could not be raised, though further reduction of the blood pressure was required.
Side-effects The side-effects are shown in Table II 
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Thirteen patients complained of nausea after ingestion of guanoxan tablets, especially in the morning. As a rule the nausea could be reduced by taking the tablets with meals. One patient developed a dry squamous eruption on the back of his hands during treatment with methyldopa. He had had similar eruptions previously when taking the same drug. Many patients complained of impotence and failure of ejaculation. These symptoms were observed with all the drugs, but were most troublesome with guanoxan and guanethidine. The patients on methyldopa who complained of this effect had all voiced the same or more serious complaints when being treated with the other two agents.
Side-effects were not recorded in 15 patients treated with methyldopa, compared with seven treated with guanoxan and seven with guanethidine. They were mainly the same patients, and in most cases the dose was low.
The red-cell, white-cell, and platelet counts, the haemoglobin value, and the serum alanine transaminase were determined in all the patients before the trial and at each change of drug. On the basis of the present trial we cannot assess the value of a combined treatment with the drugs concerned. Breckenridge and Dollery (1966) have shown that by combining methyldopa and a sympatholytic agent (bethanidine) favourable results can be obtained even in cases where methyldopa or bethanidine was without any greater effect or produced appreciable sideeffects when given alone.
The fact that tolerance may develop towards methyldopa and guanethidine during long-term treatment is not supported by our short-term trial. For this reason we cannot say anything about a possible tendency to development of tolerance towards guanoxan. Montuschi and Lovel (1964) described the cases of two patients who developed signs of liver affection after treatment with guanoxan (and other agents). Peart and MacMahon (1964) carried out liver-function tests in their 69 patients and found no signs of any effect on this function. This applies also to the present trial. Cotton and Montuschi (1966) suggested that the drug might be hepatotoxic, and they announced further studies.
Although in our opinion there is not much basis for presuming that guanoxan has a hepatotoxic effect, this is presumably the reason why this drug has not yet been introduced into Denmark.
Summary
Forty patients with moderate and severe hypertension were treated with methyldopa, guanethidine, guanoxan, and guanoclor. The study was made on a double-blind basis.
Severe side-effects occurred after the administration of guanoclor, and consequently it had to be excluded from the trial.
The study seems to show that in cases where satisfactory response is not obtained by complete diuretic therapy methyldopa is the drug of choice to be added. In cases where methyldopa has no satisfactory effect a sympatholytic agent must be given. Our results indicate that guanoxan has an advantage over guanethidine in such treatment.
Pfizer Ltd. kindly supplied all the drugs used in the trial.
